Regeneron Treatment for Ebola Recommended for Priority Evaluation by WHO

Dow Jones

May 29

By Christopher Kuo

Regeneron Pharmaceuticals's treatment for the Ebola virus was recommended for priority evaluation in clinical trials by the World Health Organization's Therapeutics Advisory Group.

The company said Thursday the WHO recommended that maftivimab, an antibody component of the company's inmazeb treatment, be studied in clinical trials of investigational treatments for Bundibugyo ebolavirus. Maftivimab has demonstrated broad activity in vitro against multiple Ebola species, including Bundibugyo, the company said.

The WHO recently declared the current outbreak of Ebola in the Democratic Republic of the Congo and Uganda a public health emergency of international concern.

Inmazeb has already been approved by the Food and Drug Administration for the treatment of infection caused by Orthoebolavirus zairense, or Zaire ebolavirus, in adult and pediatric patients. Regeneron said it is working to prepare an existing supply of maftivimab for use in potential upcoming clinical trials.

Write to Christopher Kuo at chris.kuo@wsj.com

(END) Dow Jones Newswires

May 28, 2026 16:50 ET (20:50 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2639469619"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2639469619\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2639469619?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-29 04:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2639469619","market":"hk","top_or_hot":-1,"title":"Regeneron Treatment for Ebola Recommended for Priority Evaluation by WHO","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Regeneron Pharmaceuticals's treatment for the Ebola virus was recommended for priority evaluation in clinical trials by the <a href=\"https://laohu8.com/S/WHEN\">World Health</a> Organization's <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Advisory Group. \n</p>\n<p>\n  The company said Thursday the WHO recommended that maftivimab, an antibody component of the company's inmazeb treatment, be studied in clinical trials of investigational treatments for Bundibugyo ebolavirus. Maftivimab has demonstrated broad activity in vitro against multiple Ebola species, including Bundibugyo, the company said. \n</p>\n<p>\n  The WHO recently declared the current outbreak of Ebola in the Democratic Republic of the Congo and Uganda a public health emergency of international concern. \n</p>\n<p>\n  Inmazeb has already been approved by the Food and Drug Administration for the treatment of infection caused by Orthoebolavirus zairense, or Zaire ebolavirus, in adult and pediatric patients. Regeneron said it is working to prepare an existing supply of maftivimab for use in potential upcoming clinical trials. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 28, 2026 16:50 ET (20:50 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron Treatment for Ebola Recommended for Priority Evaluation by WHO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron Treatment for Ebola Recommended for Priority Evaluation by WHO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-29 04:50</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Regeneron Pharmaceuticals's treatment for the Ebola virus was recommended for priority evaluation in clinical trials by the <a href=\"https://laohu8.com/S/WHEN\">World Health</a> Organization's <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Advisory Group. \n</p>\n<p>\n  The company said Thursday the WHO recommended that maftivimab, an antibody component of the company's inmazeb treatment, be studied in clinical trials of investigational treatments for Bundibugyo ebolavirus. Maftivimab has demonstrated broad activity in vitro against multiple Ebola species, including Bundibugyo, the company said. \n</p>\n<p>\n  The WHO recently declared the current outbreak of Ebola in the Democratic Republic of the Congo and Uganda a public health emergency of international concern. \n</p>\n<p>\n  Inmazeb has already been approved by the Food and Drug Administration for the treatment of infection caused by Orthoebolavirus zairense, or Zaire ebolavirus, in adult and pediatric patients. Regeneron said it is working to prepare an existing supply of maftivimab for use in potential upcoming clinical trials. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 28, 2026 16:50 ET (20:50 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765992.SGD","symbol_name":"FTIF - Franklin Biotechnology Discovery A Acc SGD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2639469619","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2639469619","pubTimestamp":1780001400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Regeneron Pharmaceuticals's treatment for the Ebola virus was recommended for priority evaluation in clinical trials by the World Health Organization's Therapeutics Advisory Group.The company said Thursday the WHO recommended that maftivimab, an antibody component of the company's inmazeb treatment, be studied in clinical trials of investigational treatments for Bundibugyo ebolavirus. Maftivimab has demonstrated broad activity in vitro against multiple Ebola species, including Bundibugyo, the company said.The WHO recently declared the current outbreak of Ebola in the Democratic Republic of the Congo and Uganda a public health emergency of international concern.Inmazeb has already been approved by the Food and Drug Administration for the treatment of infection caused by Orthoebolavirus zairense, or Zaire ebolavirus, in adult and pediatric patients. Regeneron said it is working to prepare an existing supply of maftivimab for use in potential upcoming clinical trials.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","BK4588":"碎股","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","BK4585":"ETF&股票定投概念","LU1917777945.USD":"安联专题基金Cl AT Acc","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","BK4139":"生物科技","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","REGN":"再生元制药公司","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC"},"translate_title":"世卫组织建议优先评估再生元治疗埃博拉病毒","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":0.9},"content_text":"By Christopher Kuo \n\n\n \n\n\n  Regeneron Pharmaceuticals's treatment for the Ebola virus was recommended for priority evaluation in clinical trials by the World Health Organization's Therapeutics Advisory Group. \n\n\n  The company said Thursday the WHO recommended that maftivimab, an antibody component of the company's inmazeb treatment, be studied in clinical trials of investigational treatments for Bundibugyo ebolavirus. Maftivimab has demonstrated broad activity in vitro against multiple Ebola species, including Bundibugyo, the company said. \n\n\n  The WHO recently declared the current outbreak of Ebola in the Democratic Republic of the Congo and Uganda a public health emergency of international concern. \n\n\n  Inmazeb has already been approved by the Food and Drug Administration for the treatment of infection caused by Orthoebolavirus zairense, or Zaire ebolavirus, in adult and pediatric patients. Regeneron said it is working to prepare an existing supply of maftivimab for use in potential upcoming clinical trials. \n\n\n \n\n\n  Write to Christopher Kuo at chris.kuo@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 28, 2026 16:50 ET (20:50 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}